Emopamil: Difference between revisions
CSV import |
No edit summary |
||
| Line 23: | Line 23: | ||
{{stub}} | {{stub}} | ||
== Emopamil gallery == | == Emopamil gallery == | ||
<gallery> | <gallery> | ||
File:emopamil.png|Emopamil | File:emopamil.png|Emopamil | ||
</gallery> | </gallery> | ||
Latest revision as of 20:28, 16 March 2025
Emopamil is a calcium channel blocker and sigma receptor ligand that has been studied for its potential use in the treatment of cardiovascular disease.
Pharmacology[edit]
Emopamil acts as a calcium channel blocker, inhibiting the influx of calcium ions into cardiac and smooth muscle cells. This action can lead to a decrease in blood pressure and a reduction in heart rate. Emopamil also has affinity for sigma receptors, which are thought to be involved in various physiological processes, including the regulation of neurotransmitter release.
Clinical Use[edit]
While emopamil has been studied for its potential use in the treatment of cardiovascular disease, it has not been approved for this use by any regulatory authority. The drug's effects on the cardiovascular system, including its ability to lower blood pressure and reduce heart rate, could potentially make it useful in the treatment of conditions such as hypertension and angina pectoris.
Side Effects[edit]
As with other calcium channel blockers, potential side effects of emopamil could include dizziness, headache, flushing, and edema. Due to its sigma receptor activity, emopamil could also potentially cause neurological side effects.
